One of the previous press releases said that the OTHER company was the one that was putting that "deal after approval" business in the wording -- in other words the other company doesn't want to pay up until they're sure that Brilacidin makes it through approval. I think basically the other party is negotiating for an option on using Bril if they think it's going to work for their devices.

And, of course, the fact that they want more material means they're continuing the study which is a great sign for its efficacy.